0B68 Whellan, David - Thomas Jefferson University
Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Whellan, David

< Back

Profile

djw150

David J. Whellen, MD, MHS, FACC, FAHA

Contact Dr. Whellen

925 Chestnut Street
Mezzanine
Philadelphia, PA 19107

(215) 955-2636
(215) 503-7420 fax

Medical School

MD, Washington University School of Medicine
Master Health Science in Clinical Research, Duke University

Residency

Hospital of University of Pennsylvania (HUP)

Fellowship

Clinical Cardiology, Duke University Medical Center

Board Certification

Internal Medicine
Cardiovascular Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Interests

Dr. Whellan is the Co-Principal Investigator of the HF-ACTION study, a NIH grant for research in heart failure and exercise training. In addition, he has served as the national PI for the PARTNERS HF study and currently sits on the steering committee for the ASCEND and TRACER-ACS trials.

He has authored over 100 peer-reviewed articles, reviews, abstracts, and book chapters on cardiomyopathy; and is an associate editor for American Heart Journal.

Publications

Most Recent Peer-Reviewed Publications

  1. Authorship in a multicenter clinical trial: The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) Scoring System Results
  2. Exercise training and pacing status in patients with heart failure: Results from HF-ACTION
  3. Stratifying patients at the risk of heart failure hospitalization using existing device diagnostic thresholds
  4. Safety and efficacy of aerobic training in patients with cancer who have heart failure: An analysis of the HF-ACTION randomized trial
  5. Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis
  6. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)
  7. Conceptual model for heart failure disease management
  8. Rationale and Design of theGUIDE-ITStudy. Guiding Evidence Based Therapy UsingBiomarker Intensified Treatment inHeart Failure
  9. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure
  10. End-of-life care in patients with heart failure
  11. Are there negative responders to exercise training among heart failure patients?
  12. Clinical implications of chronic heart failure phenotypes defined by cluster analysis
  13. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: Results of two 6-month, phase 3 studies
  14. Rationale and design of theguide-it study: Guiding evidence based therapy usingbiomarker intensified treatment inheart failure
  15. Aspirin for cardioprotection and strategies to improve patient adherence.
  16. Corrigendum to exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis Int J Cardiol. 2014 Jul 1;174(3):683-7
  17. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure
  18. Associations between Seattle heart failure model scores and medical resource use and costs: Findings from HF-ACTION
  19. PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
  20. Relationship between galectin-3 LEVELS and MINERALOCORTICOID RECEPTOR ANTAGONIST USE in HEART FAILURE: Analysis from HF-ACTION
0